Enginprime Medical Raises $12M for Heart Assist Device

Enginprime Medical, a Shanghai and Hangzhou-based innovator in percutaneous ventricular assist device (pVAD) technology, has successfully closed a $12 million Series A financing round. The significant capital infusion was exclusively led by prominent venture capital firm Qiming Venture Partners, signaling strong confidence in the company's next-generation cardiac support solutions.

The newly acquired funds are earmarked for critical development milestones. A substantial portion will finance the crucial registration clinical trial for Enginprime's flagship product, OpusOne™, within China. Additionally, the capital will support global regulatory submissions and the early-stage clinical advancement of the company's broader pVAD platform across international markets.

Founded in 2023 through Voyagers Capital's venture creation initiative, Enginprime is dedicated to engineering advanced percutaneous ventricular assist systems. The OpusOne™ device is engineered to offer superior blood flow rates while maintaining a compact catheter profile, a key differentiator in a field demanding both efficacy and minimally invasive application. This focus addresses a significant unmet need in treating advanced heart failure.

Zhiyong Liu, CEO of Enginprime Medical, expressed gratitude for the strategic backing from Qiming Venture Partners and Voyagers Capital. "This funding represents a pivotal moment as we accelerate the scaling of a globally competitive pVAD system," Liu stated. "Our commitment is to execute our clinical and regulatory strategies diligently, aiming to introduce reliable and cost-effective percutaneous ventricular assist solutions to patients worldwide."

Shuo Mao, Principal at Qiming Venture Partners, highlighted the technological innovation behind OpusOne™. "The foldable impeller design enables greater flow capacity within a lower-profile system, which is crucial for reducing clinical complications and expanding patient eligibility," Mao commented. "This represents a significant advancement in ventricular assist therapy, addressing a technological frontier with no comparable globally approved products. We believe Enginprime's expertise and differentiated approach are well-positioned to capture this market gap and deliver substantial patient benefits."

Fiona Zhang, Partner at Voyagers Capital, echoed this sentiment, emphasizing the company's strong foundation. "Enginprime emerged from our venture creation model, and the team has exceeded our expectations," Zhang noted. "We recognize a clear opportunity in the global pVAD market and are eager to support the launch of OpusOne™ in China and internationally, alongside our partners at Qiming Venture Partners." The global market for mechanical circulatory support devices, including pVADs, is projected for substantial growth, driven by an aging population and increasing prevalence of cardiovascular diseases.